SCHEMBL72398

SCHEMBL72398

CCOC(=O)C1CCC(OC(C(=O)OC(C)(C)C)(N2CCCC2)N2CCN(Cc3ccccc3)C(=O)C2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ATM Q13315 1/20 0.39
LMNA P02545 1/20 0.39
CCR8 P51685 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.37
TSHR P16473 2/20 0.37
MAPK1 P28482 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73355 0.88 ALDH1A1 (0.52) ALDH1A1PKML3MBTL1ATMCCR8
SCHEMBL72858 0.85 PKM (0.40) ALDH1A1PKMNPSR1L3MBTL1LMNA
SCHEMBL72859 0.85 PKM (0.40) ALDH1A1PKMNPSR1L3MBTL1LMNA
SCHEMBL72357 0.83 ALDH1A1 (0.39) ALDH1A1PKMLMNAMEN1KMT2A
SCHEMBL72358 0.83 ALDH1A1 (0.39) ALDH1A1PKMLMNAMEN1KMT2A
SCHEMBL71208 0.82 SMN1; SMN2 (0.44) ALDH1A1PKMNPSR1L3MBTL1MEN1
SCHEMBL72021 0.81 SMN1; SMN2 (0.43) ALDH1A1PKMNPSR1L3MBTL1MEN1
SCHEMBL71343 0.81 SMN1; SMN2 (0.43) ALDH1A1PKMNPSR1L3MBTL1MEN1
SCHEMBL73423 0.81 ALDH1A1 (0.46) ALDH1A1PKMMEN1KMT2AKDM4E
SCHEMBL73422 0.81 ALDH1A1 (0.46) ALDH1A1PKMMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885PKM 4083/4885NPSR1 1592/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885PKM 4112/4885NPSR1 1517/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885PKM 4337/4885NPSR1 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.